Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. III
6. TTEC
7. DAL
8. AWK
9. GZDIF
10. ATNI

Go back to Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
(NASDAQ: KYMR) Delayed: 90.43 +0.53 (0.59%)
Previous Close $89.90    52 Week High $ 
Open $90.68    52 Week Low $ 
Day High $92.47    P/E N/A 
Day Low $89.18    EPS $ 
Volume 1,262,295